DUBLIN--(BUSINESS WIRE)--Alkermes plc (NASDAQ: ALKS) today reported financial results for the first quarter of 2017.
“Our results this quarter reflect solid year-over-year growth of our commercial portfolio, driven by our proprietary products, VIVITROL® and ARISTADA®. Looking ahead to the remainder of the year, we remain focused on making these important medicines available to patients and driving growth,” commented James Frates, Chief Financial Officer of Alkermes. “With our strong financial position and growing commercial portfolio, we are well positioned to invest in our advancing late-stage pipeline and our commercial organization to support Alkermes’ expanding portfolio of proprietary products. Today, we are reiterating our financial expectations for 2017 that we provided in February.”
“The strength of the Alkermes business is grounded in our diversified portfolio of proprietary commercial products and late-stage development candidates, each of which represent a potential blockbuster opportunity in major CNS disease categories,” said Richard Pops, Chief Executive Officer of Alkermes. “Our late-stage pipeline continues to advance rapidly in 2017 with the planned New Drug Application submission for ALKS 5461 for the adjunctive treatment of major depressive disorder, data from the pivotal antipsychotic efficacy study for ALKS 3831 in schizophrenia and completion of the clinical registration requirements for ALKS 8700 in multiple sclerosis expected before year-end.”
